《大行報告》中金升騰盛博藥-B(02137.HK)目標價30%至52元 評級「跑贏行業」
中金髮表報告指,騰盛博藥-B(02137.HK)上週四(9日)發佈公告,旗下新冠病毒中和抗體聯合療法的兩款藥物註冊申請獲得國家藥監局批準,該聯合療法可用於治療輕型和普通型且伴有進展爲重型(包括住院或死亡)高風險因素的成人和青少年新冠病毒感染患者。由於兩款藥物獲批上市,報告上調其成功率至100%以及上調了銷售價格,維持公司今年每股虧損預測90分人民幣不變,並將明年每股盈測上調37%至1.85元人民幣。
報告採用現金流貼現(DCF)估值法,假設加權平均資金成本(WACC)爲8.7%,永續增長率爲2%;並將估值切換至2022年底,上調目標價30%至52港元,維持「跑贏行業」評級。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.